Kornimate/medical-research-clean huggingface dataset:
addition of pudendal blocks to pelvic floor physical therapy for the treatment of pelvic floor tension myalgia

Conditions: Pelvic Floor Muscle Spasm

Summary: pelvic floor tension myalgia (pftm) is increasingly noted in patients with chronic pelvic pain. pelvic floor physical therapy is typically utilized and is at times combined with other therapies such as botox injections, trigger point injections or pudendal blocks. the investigators' study will randomize newly diagnosed patients with pftm to weekly . final patient assessment will be performed at 6 months to assess durability of response. primary hypothesis: the addition of pudendal blocks to standard pelvic floor physical therapy will result in lower pain and pelvic floor muscle tension scores, lower baseline vaginal pressure and increase pelvic floor strength. secondary hypothesis: the addition of pudendal blocks to standard pelvic floor physical therapy will result in a lower pain score in a shorter time frame, resulting in faster progress through physical therapy.

participants will be identified within uc irvine urogynecology and/or pelvic floor physical therapy practice with the underlying diagnosis of pelvic floor tension myalgia. this diagnosis may be secondary to various underlying etiologies including interstitial cystitis/painful bladder syndrome, vulvodynia, endometriosis, adhesive disease, unknown etiology, etc. at the time of enrollment, participants will be randomized into one of two groups: either standard pelvic floor physical therapy with weekly saline placebo injections or standard pelvic floor physical therapy and weekly pudendal blocks for 6 weeks. standard physical therapy techniques will be utilized in both groups. weekly injections of a mixture of a steroid and local anesthetic or saline will be administered depending on the randomization. injections will be administered by a urogynecology physician. the participant and the treating physical therapist will be blinded to treatment assignment. the participant will be evaluated with for pelvic floor muscle strength and tenderness and will have pain assessed by a visual analog scale at baseline, weekly throughout the study, and at 6 months after study enrollment. vaginal electromyography will be performed and standardized questionnaires regarding pelvic floor symptoms, quality of life and sexual function will be administered at baseline, after 6 weeks of injections and at 6 months after enrollment.

Eligibility criteria:
inclusion criteria: * non-pregnant women over the age of 18 with the diagnosis of pelvic floor tension myalgia that are naive to pelvic floor physical therapy. * able to provide informed consent. * subjects must be willing to accept randomization. exclusion criteria: * previously treated with physical therapy. * an allergy to any component within the pudendal block. * bleeding disorders. * active vaginal infection. * inability to complete the questionnaires. * inability to read english (validated questionnaires are available in english only). * inability to complete the follow-up visits.

Keywords: pelvic floor muscle spasm pelvic pain physical therapy pudendal block
swiss atrial fibrillation pulmonary vein isolation registry

Conditions: Catheter-based Ablation of Atrial Fibrillation

Summary: registry of patients with atrial fibrillation undergoing catheter-based ablation of atrial fibrillation (pulmonary vein isolation) to determine long-term success rates of catheter-based ablation of atrial fibrillation (pulmonary vein isolation) and to evaluate factors associated with long-term success of catheter-based ablation of atrial fibrillation (pulmonary vein isolation).


Eligibility criteria:
inclusion criteria: * patients undergoing catheter-based ablation of atrial fibrillation (pulmonary vein isolation) exclusion criteria: * patients not able or willing to participate in this study

Keywords: atrial fibrillation pulmonary vein isolation
exercise for low back pain in children

Conditions: Low Back Pain

Summary: this study aimed to determine the efficacy of an eight-week specific exercise programme in reducing self-reported episodes and intensity of lbp, as well as modifying some of the identified risk factors for lbp, in children.


Eligibility criteria:
inclusion criteria: * children aged 12-13 years * complained of lbp in the past three months exclusion criteria: * serious spinal pathologies or deformities (e.g. severe scoliosis, spinal tumours) * neurological conditions which alter motor tone * physical disabilities (e.g. spinal cord injuries) which prevent the child from being able to stand up on their own without an orthotic device or brace, or which prevent the child from taking part in normal physical education (pe) classes * any other serious co-morbidities (e.g. cancer, severe lung pathology) * provincial sports participants, or children who were currently following a specific training programme with a biokineticist or physiotherapist * current orthopaedic procedures or fractures of the spine, pelvis, lower or upper limbs

Keywords: randomised controlled trial low back pain exercise children school-based prevalence intensity
comparison of applied behavioral analysis (aba) versus aba and risperidone

Conditions: Autistic Disorder

Summary: hypotheses: 1. preschool children with autism spectrum disorders (asds) who undergo aba treatment only will demonstrate significantly better outcomes compared to an age and severity matched control group without aba treatment. 2. preschool children with asds who undergo aba in combination with risperidone will demonstrate significantly better outcomes compared to age and severity matched children who are receiving aba alone. 3. young age, cognitive development and attentional abilities at baseline will be predictive of good socio-emotional and neuropsychological outcomes after aba treatment. 4. at baseline, children with asds will show significantly lower performances on measures of cognitive, neuropsychological, and socio-emotional functioning than age-matched typically developing controls.


Eligibility criteria:
inclusion criteria: * diagnosis of autism or severe pervasive developmental disorder (pdd) not otherwise specified (nos) according to the autism diagnosis interview-revised (adi-r) * aged 2.6 to 5.0. exclusion criteria: * fragile x or metabolic etiology of pdd symptoms * diagnosis of other central nervous system (cns) disorders * chronic serious medical problems

Keywords: autism, applied behavioral analysis, risperidone
docetaxel, oxaliplatin and 5-fu for gastric cancer with inoperable malignant bowel obstruction

Conditions: Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Peritoneal Carcinomatosis

Summary: this is a multi-center, non-randomized, 3-cohort, phase ii trial, evaluating a triplet combination of docetaxel, oxaliplatin and fluorouracil for gastric cancer with peritoneal carcinomatosis and inoperable malignant bowel obstruction.

the primary study hypothesis is that the regimen will provide a clinically meaningful bowel obstruction clearance. this trial has 3 paralleled cohorts with the same experimental regimen: cohort a (first-line therapy) will include 35 participants who have not received any palliative chemotherapy; cohort b (second-line therapy) will include 22 participants who progress after the first-line therapy; cohort c (third- or later-line therapy) plans to include 22 cases who have received two or more prior therapies for their metastatic disease.

Eligibility criteria:
inclusion criteria: * 18-75 years of age; * ecog ps ≤3; * pathologically diagnosed gastric or gastroesophageal junctional adenocarcinoma; * peritoneal carcinomatosis established by imaging data or pathological evidence; * mbo below the treitz ligament based on clinical grounds or radiological findings; * considered as inoperable mbo by two independent surgical consultants; * hb≥60g/l, wbc ≥4×10e9/l, anc≥2×10e9/l，plt≥100×10e9/l; * cr≤ upper normal limit(unl); * tbil≤1.5 unl,ast≤1.5 unl, alt≤1.5 unl, alp≤1.5 unl; * written informed consent form paticipants. exclusion criteria: * treated by a combination regimen containing all the study drugs; * allergy to any of the study drugs; * her-2 amplification or overexpression, mismatch repair protein expression deletion (dmmr), or genetic testing suggestive of high microsatellite instability (msi-h); * strangulated intestinal obstruction; * active gastrointestinal bleeding; * uncontrolled active infection; * unstable heart diseases with severe ecg abnormalities or affect clinical treatment (such as cardiac insufficiency, myocardial infarction, angina); * severe lung diseases (such as interstitial pneumonia, pulmonary fibrosis, severe emphysema, etc); * mental disorders that affect clinical treatment or central nervous system diseases; * concomitant cerebral parenchymal or meningeal metastasis; * hiv infection or untreated active hepatitis; * bowel surgery or stenting required due to obstruction; * pregnant or lactating women; * other conditions that are not suitable for participation in the study.

Keywords: malignant bowel obstruction docetaxel oxaliplatin fluorouracil
survey of covid-19 infection

Conditions: COVID-19; Infections

Summary: using online questionnaires, we will obtain data regarding covid-19 infection and treatment, including incidence rate, hospitalization rate, severity of the infection, medications, mortality rate, etc, in both hospital and communities after the change of disease control policy in china.


Eligibility criteria:
inclusion criteria: * n/a exclusion criteria: * n/a
effect of expiratory positive pressure on dynamic hyperinflation and ability to exercise with upper limbs in copd

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the study will evaluate the effect of positive airway expiratory pressure (epap) on patients with chronic obstructive pulmonary disease (copd) during submaximal upper limb exercise.

the study to be developed from this project aims to evaluate the effect of positive airway expiratory pressure (epap) on upper limb exercise-induced dynamic hyperinflation (dh) in patients with chronic obstructive pulmonary disease (copd). to this end, a cross-over study will be implemented, developed at the pulmonology department of hospital de clínicas de porto alegre. patients with moderate to very severe, clinically stable copd will be evaluated. the anthropometric data and pulmonary function will be collected from the medical records, being the study divided into two stages. first stage: at the first visit, dyspnea, quality of life will be evaluated and a maximal incremental cardiopulmonary exercise test (cpet) for upper limb with dh evaluation during exercise. patients who presented dh on incremental cpet will be invited to return for a second and third visit. in the second and third visit an endurance test will be performed with 80% of the load reached in the incremental cpet and dh determination, one of the tests performed during the application of epap through a face mask with pressure level of 10 cmh2o and another in usual breathing, with the mask without the use of the positive pressure generating valve. the sequence of the test, ie, with and without epap, will be obtained through electronic randomization. patients completing stage 1 will be invited to enter step 2. in this step, which will occur in a single visit, patients will perform a 6-minute pegboard and ring test (6pbrt) with the same monitoring of cpet in three different situations, according to randomization: habitual breathing, half-closed lip breathing (rls) and the epap mask. thus, it is expected that the application of epap through face mask and the use of rls will reduce dh during submaximal exercise with upper limb, which will be associated with the reduction of dyspnea and increased tolerance to exercise in copd patients .

Eligibility criteria:
inclusion criteria: * clinical disease stability (no signs of exacerbation within 8 weeks prior to enrollment) * receiving standard long-term bronchodilator (bd) therapy * able to perform cycle ergometer exercise for upper limbs exclusion criteria: * use artificial airways * severe comorbidities, such as heart, orthopedic or neurological diseases that are risky or make it impossible to exercise * patients on oxygen or with indication of continuous home oxygen therapy

Keywords: dyspnea cardiopulmonary exercise test positive-pressure respiration
moving forward together 4

Conditions: Breast Cancer; Physical Inactivity

Summary: this is a 3-month physical activity intervention aimed to increase moderate-intensity activity among previously inactive breast cancer survivors. participants will be eligible if they are not currently active, and have recently been diagnosed with breast cancer. upon eligibility, participants will be randomized into one of two groups. the intervention group will receive weekly guidance from a peer coach to increase their activity throughout the three month intervention. the control group will be encouraged to self-monitor their physical activity throughout the three month intervention. both groups will receive a fitbit. peer coaches will be trained to deliver the physical activity program using a web-based platform; all calls will be virtual. participants will be assessed before and after the intervention.


Eligibility criteria:
participants: inclusion criteria: * diagnosed in the past 5 years with stage 0-3 breast cancer * able to read and speak english * ambulatory * sedentary (\<30 minutes of vigorous-intensity physical activity, \<90 min of moderate-intensity physical activity in the past 6 months) * able to walk unassisted * access to a smartphone with bluetooth and internet exclusion criteria: * stage 4 cancer * medical or psychiatric problem that may interfere with protocol adherence peer mentor coaches: inclusion criteria: * current peer coach (at least one year) * have a valid email address, telephone access, and access to a tablet/computer * willing to participate in group training * willing to be supervised using platform * currently exercise for at least 60 min/week of moderate-intensity activity

Keywords: peer support
study to evaluate the drug-drug interaction of jmkx003142 in healthy subjects

Conditions: ADPKD (autosomal Dominant Polycystic Kidney Disease)

Summary: to evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of jmkx003142 in healthy subjects.


Eligibility criteria:
inclusion criteria: * fully understand the research content, process, and potential risks of this trial, voluntarily participate in the clinical trial and sign the informed consent, * healthy male and female subjects aged ≥18 years and ≤45 years old, male weight ≥50kg, female weight ≥45kg, body mass index ≥19 kg/m2 and ≤28 kg/m2, * the health of the subjects was determined by the investigator based on medical history, physical examination, clinical laboratory examination, and 12-lead electrocardiogram, all of which were determined by the investigator to be normal or not clinically significant. exclusion criteria: * hbv surface antigen, hcv antibody, hiv, or syphilis are positive during screening, * at the time of screening, the vital signs are within the following ranges: systolic blood pressure \ 140 mmhg, diastolic blood pressure \ 90 mmhg, pulse \ 100 bpm and ear temperature 37.5℃or\<35℃, * more than 5 cigarettes per day during the 3 months prior to screening, or were unable to quit smoking/containing tobacco products during the trial, * have special requirements for diet and cannot comply with the diet provided and corresponding regulations.
improving outcomes using technology for children who are dhh

Conditions: Hearing Loss; Language Development; Social Behavior

Summary: this study evaluates the efficacy of using augmentative and alternative communication (aac) technology for enhancing language development in children who are deaf or hard of hearing. half of the participants will receive aac technology with their speech and language therapy and half will continue with their usual care models.


Eligibility criteria:
inclusion criteria: * documented permanent bilateral hearing loss with severity levels clinically defined in any range (mild to profound); * identified with a language gap; * currently receiving speech-language therapy. exclusion criteria: * primary language other than english * significant motor impairments * nonverbal iq \<60 * children with severe communication disorders (i.e. autism spectrum disorders).
the effect of ultrasound on orthodontic tooth movement

Conditions: Malocclusion

Summary: to study whether or not the aevo system™ medical device enhances the rate of tooth movement in human subjects who use orthodontic braces.

the study will involve comparing the effects of tooth movement with and without ultrasound treatment in a split mouth design. treatment will consist of using the aevo system™ device for one 20 minute period per day for the duration of the trial (up to 24 weeks). tooth position measurements will be taken from eligible patients prior to commencing usage of the study device. follow-up visits will be scheduled for intra-oral clinical measurements and to take full-arch impressions. the aevo system™ consists of an ultrasound emitting mouthpiece which is wire connected to an external handheld device. the mouthpiece is placed over the teeth and over the braces every day for 20 minutes in order to deliver the therapy.

Eligibility criteria:
inclusion criteria: subjects who meet all of the following criteria will qualify for entry into the study: 1. scheduled to receive orthodontic treatment or in early stage of orthodontic treatment 2. minimum of 3 mm of extraction space (on both sides of a dental arch) to be closed either by distal movement of all 6 anterior teeth from canine to canine or by distal movement of the canines. 3. available for follow-up visits. 4. willing and able to sign written informed consent. 5. healthy. 6. has permanent dentition and between the ages of 12 and 40. 7. good oral hygiene and compliance exclusion criteria: subjects who meet any of the following criteria will be excluded from the study: 1. any compromised medical or dental condition that prevents the subject from participating in the trial or using the medical device. 2. any implanted assistive devices. 3. currently involved in any other study. 4. lives significantly outside the clinical trial site. 5. use of bisphosphonates. 6. pregnant females .

Keywords: orthodontics braces tooth
peer supported collaborative care mental health and substance use disorder care

Conditions: HIV Infections; Substance Use Disorders; Mental Health Disorder; Addiction; Opioid Use; Drug Use

Summary: this is a research study to assess the effectiveness of a peer-led collaborative care model for integrating treatment for substance use and or mental health disorders into hiv care settings. depending on whether or not participants enroll in this study, participants will be assigned randomly (by chance, like drawing a number from a hat) to one of two groups. in group 1, participants would receive usual clinical care. in group 2, participants would work with a peer-case manager who would help support participants to engage in substance use or mental health disorder care. regardless of the group participants are in, participants will fill out a survey when first enrolled in the study, and then again 12 months later.


Eligibility criteria:
inclusion criteria: * individuals 18-99 years old * accessing hiv care at the bartlett hiv clinic * screened positive for a mental health disorder or substance use disorder based on a computerized self-administered screen with patient health questionnaire (phq-9)(score\>10), general anxiety disorder (gad-7) (score\>10), national institute on drug abuse drug use screening tool: 3 question quick screen (response of "yes" to one or more heavy drinking days or "yes" to use of illegal drugs or prescription drugs for non-medical reasons. * does not currently have a mental health or substance use disorder treatment provider and or not receiving any current treatment (psychotherapy or pharmacotherapy) for mental health or substance use disorder. * english speaking exclusion criteria: • individuals lacking the capacity to consent

Keywords: collaborative care peer support
effects of doxycycline on persistent symptoms post-neuroborreliosis

Conditions: Fatigue; Radicular Pain; Cognitive Dysfunction; Paresthesia; Paresis

Summary: the aim of this randomised, double-blind crossover study was to determine whether doxycycline has an impact on the persistent symptoms post-neuroborreliosis, through alterations in the immune response and whether such an effect could influence the clinical outcome.

persistent symptoms after treatment of neuroborreliosis (nb) are not uncommon. there is currently no evidence for improvement of symptoms after repeated or prolonged antibiotic treatment. however, clinical observations have indicated that some patients improve during treatment with doxycycline (dox), but regain the symptoms some time after completed treatment. this may be due to an immunomodulatory effect of the drug. the aim of this randomised, double-blind crossover study was to determine whether dox has an impact on the persistent symptoms through alterations in the immune response and whether such an effect can influence the clinical outcome. a total of 15 patients from south-east sweden with previously adequately diagnosed nb with diverse persistent symptoms ≥6months after antibiotic treatment were randomised in a double-blind, crossover fashion to receive either dox 200 mg or placebo (pbo) once daily for three weeks, followed by a wash-out period of six weeks and a further three-weeks treatment with either dox 200 mg or pbo once daily for three weeks. the primary outcome measures were improvement of the persistent symptoms and physical and mental health, evaluated using the visual analogue scale (vas), the 36-item short-form general health survey (sf-36) and through physical examination with special emphasis on neurologic status at the follow-up visits. secondary outcome measures were changes in drug-induced antigen-stimulated and unstimulated cytokine responses.

Eligibility criteria:
inclusion criteria: * a history of adequately diagnosed and treated neuroborreliosis (presence of intrathecal borrelia-antibody production) * persistence of symptoms (with debut in conjunction with neuroborreliosis) of typical character, such as headache, radiculitis, cognitive dysfunction, fatigue, mood disorders, paresthesia or paresis \> 6 months post-treatment of neuroborreliosis exclusion criteria: * systemic immunosuppression (treatment with corticosteroids, cytostatics etc) * ongoing infection at inclusion * allergy against doxycycline * pregnancy * breast feeding * psychiatric disease * multiple sclerosis * rheumatoid arthritis * diabetes mellitus type 1 or ii * inflammatory systemic diseases * liver ohc kidney dysfunction * treatment with didanosine, quinapril, antacids * malignancy

Keywords: persistent symptoms doxycycline placebo neuroborreliosis